Hierarchical Cascade‐Activated Microneedle Patches for Photothermal and Chemotherapy Gaizhen Kuang, Wenzhao Li, Yu Wang, Qingfei Zhang, Hua Jiang Abstract Chemotherapy and photothermal therapy (PTT) are recognized as effective strategies in cancer treatment. However, the challenge remains in effectively targeting these therapeutic modalities to the tumor site to improve therapeutic effects. Here, a novel hierarchical cascade‐activated microneedle (MN) patch (MNDOX@MICG) for photothermal and bioorthogonal chemotherapy was developed. The MN patch was fabricated by integrating hydrogel microspheres (MICG) containing tetrazine‐functionalized indocyanine green (Tz‐ICG) into the MN arrays. Upon irradiation with near‐infrared light, Tz‐ICG with high photothermal conversion efficiency can elevate the temperature of MN, facilitate PTT, and trigger the release of trans‐cyclooctene‐conjugated doxorubicin (TCO‐DOX) encapsulated in MN. Then, the gradually released Tz‐ICG from MICG can react with TCO‐DOX via a specific inverse electron‐demand Diels‐Alder bioorthogonal reaction, thereby restoring the anticancer activity of DOX. Consequently, MNDOX@MICG can efficiently eradicate tumor cells in vitro and significantly inhibit the growth of postsurgical melanoma by combining PTT with bioorthogonal chemotherapy. These findings highlight the practical value of such a hierarchical cascade‐activated MN patch for versatile drug delivery and biomedical applications. Hierarchical cascade‐activated microneedle patches (MNDOX@MICG) were developed by integrating microfluidic hydrogel microspheres into microneedle arrays, enabling precise integration of photothermal therapy (PTT) and bioorthogonal chemotherapy. Under near‐infrared irradiation, the MNDOX@MICG showed efficient Tz‐ICG‐mediated photothermal performance and triggered a bioorthogonal reaction to restore DOX's anticancer activity for synergistic tumor suppression. Highlights Hierarchical cascade‐activated microneedle patches (MNDOX@MICG) are developed by integrating microfluidic hydrogel microspheres into microneedle arrays.The MNDOX@MICG loaded with TCO‐DOX and Tz‐ICG showed efficient photothermal therapy performance and bioorthogonal chemotherapy ability.The microneedle system significantly inhibits postsurgical melanoma growth, providing an effective strategy for cancer combination therapy. Introduction Cancer represents a prominent worldwide public health problem, significantly affecting human survival and overall well‐being []. Chemotherapy, regarded as one of the primary conventional treatment modalities, has long been an indispensable part of cancer therapy [, ]. Specifically, the strategy of activating prodrugs through bioorthogonal reactions for chemotherapy, such as doxorubicin (DOX) prodrugs, has achieved promising therapeutic effects [, , ]. However, the restricted bioavailability and administration vulnerability of prodrugs lead to inadequate drug levels at the tumor, diminishing therapeutic effectiveness [, ]. Besides, adverse effects, drug resistance, and tumor complexity result in unsatisfactory therapeutic outcomes of chemotherapy [, ]. In comparison, photothermal therapy (PTT) has gained substantial interest due to its low invasiveness, strong spatiotemporal specificity, and reliable controllability [, , , ]. To attain enhanced antitumor efficacy, a variety of drug delivery vehicles (including films, hydrogels, fibers, and microspheres) have been engineered through the combination of chemotherapy and PTT [, , , , ]. Unfortunately, the combination delivery systems commonly encounter several challenges that hinder their broader application. The straightforward integration of drugs/photosensitizers and carrier materials often leads to uncontrollable release behavior []. In addition, the unavoidable release of toxic therapeutic drugs or photosensitizers from these delivery carriers can cause significant harm to healthy tissues [, ]. Therefore, the development of a smart system that integrates intelligent drug activation with innovative therapeutic modalities holds great promise for tumor therapy. In this paper, we report a novel hierarchical cascade activated microneedle (MN) patch for photothermal and chemotherapy of melanoma, as schemed in Figure . MN patch, as a minimally invasive transdermal drug delivery strategy, has advantages such as high drug loading capacity, good biocompatibility, painlessness, minimal damage, self‐management, simple handling, and wide application [, , ]. As a promising local drug delivery system, MN patches can effectively load therapeutic reagents such as chemical drugs, nanomedicines, proteins, and nucleic acids, achieving controllable and continuous release to meet the treatment needs of various diseases [, , ]. Based on these characteristics and advantages, the MN patch system can achieve more ideal tumor treatment effects compared with traditional drug delivery methods [, ]. Specifically, research has fabricated a bioorthogonal catalytic MN patch that facilitates the localized activation of doxorubicin (DOX) prodrug at subcutaneous melanoma sites, thereby restoring the therapeutic anticancer efficacy of the parent drug []. Although it achieved certain treatment effects, the system lacks a well‐defined structural design and combination therapy potential, resulting in the substandard anticancer performance. Therefore, it is conceived that by elaborating a design, a multifunctional MN therapeutic platform could be developed to improve tumor therapy efficiently. Herein, we combined the microfluidic hydrogel microspheres and the MN arrays together to present a novel microsphere‐integrated hierarchical cascade activated MN patch (MNDOX@MICG) for controllable bioorthogonal prodrug activation and combination therapy (Figure ). The hydrogel microspheres (MICG), containing tetrazine‐functionalized indocyanine green (Tz‐ICG), were generated by a flexible capillary microfluidic electrospray method [, ]. These MICG were embedded into the MN arrays containing trans‐cyclooctene‐conjugated doxorubicin (TCO‐DOX). Compared to currently existing drug delivery systems, the design of microspheres in MN facilitates the separate loading of bioorthogonal prodrug molecules. This approach prevents premature activation of the prodrug molecules and achieves a gradual drug release behavior, thereby enhancing the localized delivery and action of the drug. As a kind of biocompatible near‐infrared (NIR) absorption material, the Tz‐ICG has a high photothermal conversion efficiency, which could induce the PTT ability of the MNDOX@MICG. Besides, the photothermal effect can accelerate the release of encapsulated TCO‐DOX and Tz‐ICG, thereby facilitating the specific inverse electron‐demand Diels–Alder (IEDDA) reaction. As a typical bioorthogonal reaction, IEDDA can occur without the need of metal catalysts [, ]. This reaction utilizes tetrazine moieties to undergo cycloaddition with highly strained cycloalkenes, presenting significant potential for various biomedical applications. Through this bioorthogonal reaction, Tz‐ICG successfully activated TCO‐DOX, thereby restoring the anti‐tumor activity of DOX. Based on these features, MNDOX@MICG exhibited effective in vitro tumor cell cytotoxicity and significantly inhibited post‐surgical melanoma growth by combining PTT and bioorthogonal chemotherapy, accompanied by good safety. These results emphasize that such a hierarchically cascade‐activated MN patch represents an ideal candidate for controllable drug delivery, providing an effective and versatile therapeutic strategy for diverse biomedical applications. Results and Discussion The study employed a glass capillary microfluidic electrospray platform to fabricate Tz‐ICG encapsulated microspheres (illustrated in Figure and Supporting Information : Figure S1). The initial steps involved introducing a precursor mixture of polyethylene glycol diacrylate (PEGDA), Tz‐ICG compounds, and a photopolymerization initiator into the microfluidic setup. Within this setup, electrostatic and gravitational forces facilitate droplet formation. Subsequently, the generated droplets were rapidly frozen in a liquid nitrogen bath before undergoing ultraviolet irradiation for polymerization, resulting in the final MICG formulation. As a control group, empty microspheres (MB) lacking therapeutic agents were also manufactured simultaneously. Morphological assessments conducted via confocal laser scanning microscopy (CLSM) and scanning electron microscopy (SEM) demonstrated that both MB and MICG maintained structural uniformity, displaying spherical geometries with diameter measurements of 150.8 ± 19.4 μm and 151.0 ± 19.1 μm, respectively (Figure ). Due to the incorporation of Tz‐ICG, the MICG exhibited intense red fluorescence under excitation light as observed through CLSM, whereas this fluorescence was absent in the MB (Figure ). Besides, the MICG appeared green in the tubes, in contrast to the MB, which appeared white (Supporting Information : Figure S2). The spherical morphology of the microspheres was examined through SEM, revealing a significant reduction in the average diameter subsequent to the dehydration process (Figure ). The hierarchical MN patches were manufactured through a template replication methodology [, ]. Figure illustrates the preparation processes, where a homogeneous mixture of methacrylate gelatin (GelMA) and TCO‐DOX was combined with microspheres before being precisely deposited into the tip regions of a negative mold. Subsequently, an additional mixture of GelMA was applied to form the backing layer within the mold. It should be noted that the TCO‐DOX conjugate was prepared following established synthetic protocols [, ], with its successful formation confirmed by characteristic 1H NMR signals shown in Supporting Information : Figures S3 and S4. Upon UV exposure, both the tip and backing components underwent complete photopolymerization and curing. The final hierarchical MN patch was then obtained through demolding after UV‐induced crosslinking. As shown in Figure , the fabricated device exhibited a well‐defined architecture comprising a 10 × 10 array of conical microneedles mounted on a 12 × 12 mm2 backing substrate. Individual needles featured geometric parameters of 960 μm base diameter and 800 μm length. SEM analysis further revealed the highly ordered spatial distribution of MN across the backing layer (Figure ), while cross‐sectional examination clearly visualized the embedded microspheres (Figure ). Mechanical characterization indicated each needle could withstand compressive loads up to 0.38 N (Figure ), collectively demonstrating the successful production of structurally intact and mechanically robust hierarchical MN patches. For the convenience of explanation, the MN patches are named as follows: MNB@MB for those with MB but without loading TCO‐DOX, MNB@MICG for those with MICG but without loading TCO‐DOX, MNDOX@MB for those with MB and TCO‐DOX, and MNDOX@MICG for those with both MICG and TCO‐DOX. As a widely employed photothermal therapeutic agent, ICG serves as the foundational compound for developing Tz‐ICG derivatives [, ]. Given the structural homology among these compounds, we hypothesized that Tz‐ICG would exhibit similar photothermal conversion properties. This hypothesis led to a systematic investigation of the thermal response profiles demonstrated by the MN system. As shown in Figure , under 808 nm laser exposure, both MNB@MICG and MNDOX@MICG achieving temperature elevation of Δ29.5°C and Δ30.0°C, respectively, within a 3‐min irradiation period. MNB@MB and MNDOX@MB, lacking MICG components, showed minimal thermal response under the same experimental conditions. Besides, the photothermal temperature changes of the MNDOX@MICG were significantly increased with the increase in the laser power density (Figure ). Remarkably, the MN system maintained reproducible thermal output through five consecutive NIR irradiation cycles (Figure ), demonstrating the exceptional photostability of the system. Infrared thermographic analysis provided spatial‐temporal visualization of the photothermal activation dynamics across the MN arrays (Figure ). These experimental findings collectively verified the superior photothermal performance of MN platforms incorporating Tz‐ICG, thereby providing a promising technological basis for the development of photothermally mediated therapeutic interventions. The absorption spectra of TCO‐DOX and Tz‐ICG were first detected before measuring the release profiles of the hierarchical MN system (Supporting Information : Figure S5). Subsequently, a quantitative analysis of the drug‐release profiles of the system was conducted utilizing UV‐vis‐NIR spectroscopy. The TCO‐DOX encapsulated within the MN structures exhibited relatively rapid release kinetics in the absence of irradiation, achieving a cumulative release of 52.8% within a 24‐h observation period (Figure ). Over the next 48 h, the release amount gradually increased to 60.3% at 72 h. Upon exposure to irradiation, the release rate of TCO‐DOX was significantly enhanced, with the release amount rapidly reaching 82.1% within 24 h and ultimately 90.2% at 72 h (Figure ). In contrast, the Tz‐ICG loaded in the MICG displayed much slower release characteristics, requiring extended duration to achieve comparable release percentages, regardless of irradiation (Figure ). This differential release behavior highlights the capacity of such hierarchical MN system for sequential drug release, a feature that could contribute to controlled drug activation and prolonged anticancer therapeutic applications. The anticancer effect of MNDOX@MICG was evaluated through CCK‐8 proliferation assay and live/dead staining assay. Primary investigations focused on the cytotoxic profile change of TCO‐DOX by comparing its bioactivity pre‐ and post‐activation by Tz‐ICG. Quantitative cytotoxicity analysis revealed distinct differences in therapeutic potency between free DOX and TCO‐DOX. Specifically, free DOX exhibited an IC50 value of 0.39 μM, whereas the TCO‐conjugated prodrug showed markedly attenuated cytotoxicity with an IC50 of 10.5 μM (Figure ). This significant reduction in cytotoxicity is attributed to the covalent bonding between the cyclooctene moiety and the amino group at the anticancer active site of DOX []. Subsequent bioorthogonal activation through the IEDDA reaction with Tz‐ICG restored therapeutic efficacy (Supporting Information : Figure S6), decreasing the IC50 to 0.48 μM, comparable to that of free DOX. Control experiments demonstrated the negligible cytotoxicity of Tz‐ICG (Supporting Information : Figure S7), thereby confirming the biocompatibility of the reaction. Next, a transwell co‐culture system with B16F10 melanoma cells seeded in lower compartments and MNDOX@MICG applied to upper compartments was used to investigate the anticancer effect of the MN systems (Figure ). After a 5‐min photoirradiation followed by a 24‐h incubation period, CCK‐8 assays indicated treatment‐specific responses. The MNB@MB and MNB@MICG treatment groups showed minimal proliferative interference, whereas MNDOX@MB induced moderate growth suppression (Figure ). Notably, non‐irradiated MNDOX@MICG demonstrated superior cytotoxic efficacy compared to MNDOX@MB, while photothermally activated MNB@MICG (+) exhibited enhanced anticancer ability relative to its non‐irradiated form. The most significant anticancer effects were observed in the MNDOX@MICG (+) treatment group by the combination of bioorthogonal chemotherapy and PTT. These quantitative findings were also corroborated by the live/dead staining assay (Figure ), demonstrating the superior anticancer performance of the dual‐modality therapeutic platform of MNDOX@MICG. The in vivo therapeutic efficacy of MNDOX@MICG was then investigated in detail in a subcutaneous melanoma model. Figure illustrates the experimental treatment protocol. The photothermal performance of the MN system was then evaluated. As shown in Figure , the tumor sites treated with MNB@MICG or MNDOX@MICG exhibited rapid temperature elevation within 5 minutes of NIR irradiation, demonstrating effective photothermal ability. In contrast, the treatment groups of MNB@MB and MNDOX@MB showed minimal temperature variation at irradiated tumor sites. After that, the monitoring of tumor progression demonstrated the unimpeded growth in both saline‐treated and MNB@MICG‐treated groups, attributable to the unlimited proliferation of B16F10 cells (Figure ). Comparative efficacy analysis demonstrated that while free DOX and MNDOX@MB resulted in modest tumor suppression, the MNDOX@MICG treatment displayed significantly superior outcomes. This enhanced efficacy is attributed to the sequential release of the Tz‐ICG and TCO‐DOX components, followed by their bioorthogonal activation, which amplifies the chemotherapeutic effects. Importantly, PTT mediated by MNB@MICG alone also exhibited measurable antitumor activity. The most substantial therapeutic response was observed with the treatment of MNDOX@MICG with NIR irradiation, leading to the maximal inhibition of tumor growth (Figure ). Collectively, these findings indicate that the hierarchical MN platform, through its integration of PTT and bioorthogonal chemotherapy, constitutes a highly effective multimodal strategy for cancer treatment. To elucidate the therapeutic mechanism of the MN system, comprehensive histological evaluations were performed utilizing hematoxylin‐eosin (H&E) staining, terminal‐deoxynucleotidyl transferase‐mediated nick end labeling (TUNEL) apoptosis assays, and Ki67 analysis. Histopathological assessment via H&E revealed densely populated tumor cell populations with intact nuclear morphology in both untreated controls and the non‐irradiated MNB@MICG group (Figure ). In contrast, the MNDOX@MICG (+) intervention group exhibited pronounced tumor cell destruction relative to the other treatment groups. Complementary TUNEL analysis also confirmed maximal apoptotic induction specifically in MNDOX@MICG (+)‐treated group (Figure ), validating the synergistic potential of combined PTT and bioorthogonal chemotherapy. Ki67 immunostaining further established that MNDOX@MICG (+) administration correlated with the most substantial suppression of tumor cell proliferation activity (Figure ). Notably, during the experimental processes, all mice remained alive, and their body weights gradually increased (Supporting Information : Figure S8). However, it is important to note that treated with DOX experienced a reduction in weight due to treatment‐associated systemic toxicity. Despite this, the histological integrity of major organ systems was preserved across all therapeutic regimens (Figure ), thereby collectively affirming the favorable biosafety profile of the hierarchical MN platform. Conclusion In summary, this study presents an engineered hierarchical cascade activated MN platform with spatiotemporal control over bioorthogonal reaction agents for combinatorial melanoma intervention. The system design loaded TCO‐DOX within MN needles and Tz‐ICG in microspheres, enabling temporally controlled drug release in response to NIR irradiation. Upon tumor application, MICG‐encapsulated Tz‐ICG demonstrated robust photothermal conversion efficiency under NIR exposure for PTT. Notably, the rapidly released TCO‐DOX from the MN needles underwent sequential activation via an IEDDA reaction with Tz‐ICG released from MICG, effectively restoring the chemotherapeutic efficacy of DOX. Thus, the fabricated MNDOX@MICG platform exhibited pronounced anticancer activity, achieving significant tumor growth suppression through the synergistic effects of photothermal ablation and bioorthogonal chemotherapy, while maintaining exceptional systemic safety. Collectively, this therapeutic platform establishes a novel paradigm for spatially defined drug activation and delivery, demonstrating considerable translational potential in precision tumor therapy. Methods Materials Tz‐ICG and (E)‐Cyclooct‐2‐en‐1‐yl (4‐nitrophenyl) carbonate ((2E)‐TCO‐PNB) were bought from Confluore Biotechnology Co. Ltd. Poly(ethylene glycol) diacrylate (PEGDA), doxorubicin hydrochloride (DOX·HCl), and the photoinitiator lithium phenyl(2,4,6‐trimethylbenzoyl) phosphinate (LAP) were commercially bought from Aladdin Biochemical Technology. The Calcein‐AM/propidium iodide (PI) dual‐staining kit was obtained from Meilun Biotechnology Co. Ltd. The Cell Counting Kit‐8 (CCK‐8) proliferation assay system was bought from Beyotime Institute of Biotechnology. Synthesis of TCO‐DOX The synthesis of TCO‐DOX was according to the previous reports []. The 1H NMR spectra of (2E)‐TCO‐PNB, DOX, and TCO‐DOX are shown in Supporting Information : Figures S3 and S4, which indicate the successful preparation of TCO‐DOX. Preparation of MICG The precursor solution containing PEGDA (5% (w/w)), Tz‐ICG (10 mg/mL), and LAP photoinitiator (1% (v/v)) was injected into a glass capillary‐based microfluidic system with an 80 μm orifice diameter. Experimental parameters were precisely controlled, with the syringe pump operating at a flow rate of 1 mL/h and the electrostatic generator maintaining 4 kV output. Subsequently, the droplets generated under the high‐voltage electric field were collected into liquid nitrogen and further cross‐linked by UV light to obtain the MICG. For comparative analysis, blank microspheres (MB) were prepared following the same procedures excluding drug incorporation. Structural characterization of both MB and MICG was performed using optical microscopy and SEM. Fabrication of MNDOX@MICG The fabrication process began with the preparation of a composite hydrogel solution containing 10% (w/w) GelMA, MICG, 1 mg/mL TCO‐DOX, and LAP. This precursor formulation was introduced into MN‐negative molds, followed by centrifugal filling of the conical microcavities. Subsequently, a secondary coating solution comprising 10% GelMA and 1% LAP was applied to encapsulate the MN backing. Photopolymerization was achieved through 30‐s UV irradiation, resulting in solidification of the MNDOX@MICG construct. The fully cross‐linked MN array was then delicately demolded. For experimental control, three variant MN formulations were prepared: MNB@MB, MNB@MICG, and MNDOX@MB. Structural evaluation of all MN patches was conducted using both optical microscopy and SEM. The Photothermal Effect of MN Patches The thermal response characteristics of the MN arrays under NIR irradiation were systematically examined using an 808 nm wavelength laser system. Quantitative thermal profiling was performed by recording the temporal temperature variations across different MN formulations with an infrared thermographic camera. The influence of irradiation parameters on photothermal conversion efficiency was determined through controlled modulation of laser output power. To evaluate the photothermal stability, the MN system was subjected to three “On‐Off” cycles. Each cycle comprised 100 s of continuous laser irradiation, followed by 300 s of natural cooling under non‐irradiating conditions. Drug Release Study Using a UV‐Vis‐NIR spectrophotometric system, the absorption spectra of TCO‐DOX and Tz‐ICG were recorded (Supporting Information : Figure S5). Then, to facilitate testing and operation, the release kinetics of Tz‐ICG and TCO‐DOX were investigated from MNB@MICG and MNDOX@MB, respectively. For TCO‐DOX measurement, the MNDOX@MB was placed in a 50 mL centrifuge tube containing 20 mL of PBS. Then, the tube was subjected to controlled oscillation (100 rpm) in a thermostatic chamber maintained at physiological temperature (37°C). At the predetermined time point, 1 mL of release medium was extracted for spectrophotometric quantification of released TCO‐DOX. Equal volume of PBS was replenished to maintain a constant volume. Parallel procedures were administered for MNB@MICG systems, where Tz‐ICG release was monitored at predetermined intervals using the same analytical methodology. In Vitro Antitumor Study The experimental protocol began with the seeding of B16F10 melanoma cells at a density of 5 × 104 cells per well in the down chambers of 24‐well transwell plates, allowing 12 h for cellular adhesion. After that, diverse MN formulations were administered into the top chambers. Experimental groups receiving MNB@MICG or MNDOX@MICG interventions were exposed to NIR laser irradiation for 5 min before 24‐h culture incubation, whereas control groups remained in dark condition throughout the incubation period. To quantitatively evaluate the cytotoxic efficacy of MN formulations against tumor cells, parallel assessments were conducted using Calcein‐AM/PI dual staining assay and CCK‐8 assay. Tumor Inhibition In Vivo The experimental protocol was initiated with subcutaneous implantation of 1 × 106 B16F10 melanoma cells to the right flank of the mice. Then, the tumors were allowed to progress until volumes reached approximately 100 mm3. After that, 70% of tumor in each mouse was resection to establish the postoperative recurrence model. To evaluate the photothermal therapeutic potential of MN systems, four distinct formulations including MNB@MB, MNDOX@MB, MNB@MICG, and MNDOX@MICG were topically administered to the residual tumor tissue. Following a standardized 5‐min NIR laser irradiation, thermal response images of mice were quantitatively recorded using infrared thermal imager. Subsequently, the experimental processes were randomly divided into seven treatment groups (5 mice/group) including saline, free DOX, MNDOX@MB without irradiation, MNB@MICG without irradiation, MNDOX@MICG without irradiation, MNB@MICG with irradiation, and MNDOX@MICG with irradiation. During the treatment processes, the body weight and tumor volume of each mouse were monitored every 2 days. At the end of the experiments, primary organs and tumors were obtained and underwent standardized fixation in 4% paraformaldehyde solution and subsequent microtome sectioning at 5 μm thickness for H&E, TUNEL, and Ki67 histological analyses. Statistical Analysis Quantitative results are presented as the mean ± standard deviation throughout the study. Statistical significance was calculated via unpaired Student's t‐tests. *p < 0.05, **p < 0.01, ***p < 0.001. Ethics Statement The animal experiments were approved by the Animal Ethics Committee of the Wenzhou Institute, University of Chinese Academy of Sciences (approval WIUCAS24090303), and complied with the recommendations of the academy's animal research guidelines. Contributor Information Yu Wang, Email: yuwang@wiucas.ac.cn. Qingfei Zhang, Email: zhangqf91@163.com. Hua Jiang, Email: zrjh@zju.edu.cn.